Business Context and Reporting Period
This Form 8-K is filed by Graphite Bio, Inc. (not LENZ Therapeutics, Inc.) on August 11, 2022. The report serves to announce the company's financial results and business progress for the quarter ended June 30, 2022. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text provided is a cover page and does not contain specific numerical data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no specific financial values are available in this document.
Material Changes
The filing does not provide comparative data or specific material changes versus the prior period. It only indicates that a press release containing the second-quarter 2022 results has been issued.
Guidance, Outlook, and Risks
The document states that the company announced "Recent Business Progress" alongside its financial results. However, the text does not include specific guidance, management commentary, risk factors, or details on contingencies. The filing explicitly states that the information is not "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the correct registrant name is Graphite Bio, Inc. (ticker: GRPH), not LENZ Therapeutics, Inc.
- Review Exhibit 99.1 (the Press Release) for actual revenue, net loss, and cash position figures.
- Confirm the specific details of the "Recent Business Progress" mentioned in the announcement.
- Check for any updated guidance or clinical trial milestones in the full press release.